GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Revenue

CRBU (Caribou Biosciences) Revenue : $11.48 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Revenue?

Caribou Biosciences's revenue for the three months ended in Sep. 2024 was $2.02 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $11.48 Mil. Caribou Biosciences's Revenue per Share for the three months ended in Sep. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.13.

During the past 12 months, the average Revenue per Share Growth Rate of Caribou Biosciences was -72.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 5 years, Caribou Biosciences's highest 3-Year average Revenue per Share Growth Rate was 2.90% per year. The lowest was 1.50% per year. And the median was 2.20% per year.


Caribou Biosciences Revenue Historical Data

The historical data trend for Caribou Biosciences's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences Revenue Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
5.79 12.36 9.60 13.85 34.48

Caribou Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.66 3.56 2.43 3.46 2.02

Competitive Comparison of Caribou Biosciences's Revenue

For the Biotechnology subindustry, Caribou Biosciences's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caribou Biosciences's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Revenue distribution charts can be found below:

* The bar in red indicates where Caribou Biosciences's Revenue falls into.



Caribou Biosciences Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Caribou Biosciences  (NAS:CRBU) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Caribou Biosciences Revenue Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Caribou Biosciences Business Description

Traded in Other Exchanges
N/A
Address
2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Executives
Syed Ali-aamir Rizvi officer: Chief Medical Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner officer: See Remarks CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson director C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan officer: Chief Business Officer C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron director C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting director 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz director, officer: See Remarks C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne officer: See Remarks CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710

Caribou Biosciences Headlines

From GuruFocus